

# CONTENTS

<b>Preface</b>	<b>xix</b>
<b>Notes for Organization and Classification</b>	<b>xxi</b>
<b>Abbreviations</b>	<b>xxiii</b>
<b>1 Introduction</b>	<b>1</b>
1.1 Nomenclature and Definitions, 1	
1.1.1 Valency, 1	
1.1.2 Linkers, 3	
1.1.3 Scaffolds, 4	
1.1.4 Ligand Density, 7	
1.1.5 Homo- and Heterovalent Molecules, 7	
1.2 Mechanistic Aspects of Multivalent Interaction, 9	
1.2.1 Affinity Constant and Avidity, 9	
1.2.2 Thermodynamics, 12	
1.2.3 Kinetics, 18	
1.2.4 Steric Effects, 19	
1.3 Biological Roles of Multivalent Ligands, 20	
<b>2 Multivalent Molecules Applied to Viral Targets</b>	<b>23</b>
2.1 Influenza Virus, 23	
2.1.1 Hemagglutinin, 23	
2.1.1.1 Divalent Sialic Acid, 23	
2.1.1.2 Tetravalent Sialoside, 26	
2.1.1.3 Dendrimers Presenting Sialosides, 26	

- 2.1.1.4 Sialic Acid Displayed in Liposomes, 29
- 2.1.1.5 Polymerized Liposome Presenting Sialic Acid, 32
- 2.1.1.6 Sialic Acid in Langmuir–Blodgett Monolayers, 35
- 2.1.1.7 Sialic Acid Presented on Biopolymer Surfaces, 36
- 2.1.1.8 Poly(acrylamide) Presenting Sialosides, 36
- 2.1.1.9 Poly(acrylic acid) Presenting Sialosides, 37
- 2.1.1.10 Poly(acrylamide) Presenting C-Sialosides, 37
- 2.1.1.11 Postmodification of Activated Polymers, 38
- 2.1.1.12 Modes of Action of Polymeric Sialosides, 39
- 2.1.1.13 OPTCOL Assay, 40
- 2.1.1.14 *ter*-Poly(acrylic acid) Presenting Sialosides, 41
- 2.1.1.15 Poly(glutamic acid) Presenting Lyso-gangliosides, 42
- 2.1.1.16 Poly(glutamic acid) Bearing Sialic Acid–Containing Trisaccharides, 42
- 2.1.1.17 Poly(acrylamide) Bearing Sialic Acid Linked at the C<sub>4</sub> Position, 44
- 2.1.1.18 Poly(acrylamide) Tethering 9-*O*-Acetylsialosides, 45
- 2.1.1.19 Neoglycoprotein Displaying Sialic Acids, 45
- 2.1.1.20 Natural  $\beta$ -Inhibitors, 47
- 2.1.2 Neuraminidase, 47
  - 2.1.2.1 Poly(glutamic acid) Presenting NA Inhibitors, 48
- 2.2 Human Immunodeficiency Virus, 49
  - 2.2.1 HIV-1 Protease, 49
    - 2.2.1.1 Divalent Terminal Peptides, 50
  - 2.2.2 HIV-1 Reverse Transcriptase, 51
    - 2.2.2.1 Heterodimers Composed of NRTI and NNRTI, 51
  - 2.2.3 Glycoprotein 120 (gp120) on Viral Surfaces, 53
    - 2.2.3.1 Neoglycoprotein-Displaying CD4 Peptide, 55
    - 2.2.3.2 Galactosyl Ceramide Immobilized on Viral Surfaces, 55
    - 2.2.3.3 Multivalent Anions, 57
    - 2.2.3.4 Bivalent Antagonists of CXCR4, 59
  - 2.2.4 Surface Carbohydrates on HIV, 60
    - 2.2.4.1 Oligomannose Sugars Present on gp120, 60
    - 2.2.4.2 Modes of CVN Recognition, 62
- 2.3 Rotavirus, 63
- 2.4 Polyoma Virus, 64
- 2.5 Picorna Virus, 65

- 2.6 Respiratory Syncytial Virus, 66
- 2.7 Dengue Virus, 67
- 2.8 Nucleic Acids of Viruses, 68
  - 2.8.1 RNA–Protein Interactions, 68
    - 2.8.1.1 Neomycin B Linked to Acridine, 69
    - 2.8.1.2 Neamine Linked to Pyrene–Carboxylic Acid, 69
  - 2.8.2 RNA–Enzyme Interactions, 70
  - 2.8.3 Binders to the Minor Groove of Viral DNA, 71
    - 2.8.3.1 Hairpin-Shaped Polyamide Dimers, 71
    - 2.8.3.2 H-Shaped Polyamide Dimers, 73
    - 2.8.3.3 Naturally Occurring Dimers, 74
- 2.9 Synthetic Multivalent Vaccines, 77
  - 2.9.1 Peptide-Based Anti-influenza Vaccines, 77
  - 2.9.2 Gp41-Based Anti-HIV Vaccine, 78
  - 2.9.3 Peptide-Based Anti-FMDV Vaccines, 78

### 3 Multivalent Molecules Applied to Bacterial Targets 79

- 3.1 Targets in Bacterial Cell Membranes, 79
  - 3.1.1 D-Ala-D-Ala Peptide Precursors, 79
    - 3.1.1.1 Mode of Action by Antibiotics of the Vancomycin Class, 79
    - 3.1.1.2 Dimerization of Glycopeptide Antibiotics, 82
    - 3.1.1.3 Di- and Trivalent Vancomycin, 84
    - 3.1.1.4 Cyclic Dimers of Eremomycin, 96
    - 3.1.1.5 Polyvalent Vancomycin Constructs, 97
    - 3.1.1.6 Heterobivalent Vancomycin Constructs, 99
    - 3.1.1.7 Multivalent Vancomycin Mimics, 103
    - 3.1.1.8 Catalytic Vancomycin Mimics, 104
    - 3.1.1.9 Presentation of Glycopeptide Molecules on Bacterial Surfaces, 105
  - 3.1.2 Lipid A, 108
    - 3.1.2.1 Cholate-Based Polymyxin Mimics, 108
    - 3.1.2.2 *ter*-Cyclopentane–Based Polymyxin Mimics, 109
    - 3.1.2.3 Natural Multivalent Molecules Bound to Lipid A, 110
  - 3.1.3 *Helicobacter pylori* Adhesin Receptor, 112
    - 3.1.3.1 Synthetic Multivalent Inhibitors of *H. pylori*, 112
  - 3.1.4 *Streptococcus suis* Hemagglutinin, 117
  - 3.1.5 *Escherichia coli* FimH Adhesin, 117
    - 3.1.5.1 Physical Forces Involved in Bacterium–Cell Adhesion, 118

- 3.1.5.2 Polyvalent Inhibitors of *E. coli* Adhesin, 119
- 3.1.5.3 Presentation of Mannosides on Gold Nanoparticles, 119
- 3.1.6 *E. coli* Chemoreceptors, 120
  - 3.1.6.1 Polyvalent Galactosides as an *E. coli* Chemoattractant, 121
  - 3.1.6.2 Polyvalent Glucosides in the Chemotaxis of Gram-Positive Bacteria, 124
- 3.1.7 Nonbacterial Lectins, 124
- 3.1.8 *Staphylococcus aureus* Efflux Pumps, 125
- 3.2 Bacterial Toxins, 126
  - 3.2.1 Heat-Labile Enterotoxins, 126
    - 3.2.1.1 Pentavalent Galactosides, 127
    - 3.2.1.2 Multivalent Inhibitors Displayed on a Solid Support, 128
  - 3.2.2 Cholera Toxin, 129
    - 3.2.2.1 Galactoside-Presenting Pentavalent Inhibitors, 130
    - 3.2.2.2 Mode of Action of Pentavalent Galactosides, 133
    - 3.2.2.3 Dendrimer-Based Multivalent Lactosides, 133
    - 3.2.2.4 Polymerized Liposomes Incorporating GM<sub>1</sub>, 133
    - 3.2.2.5 Liposomes Presenting Fluorescent GM<sub>1</sub>, 136
  - 3.2.3 Shigalike Toxin, 136
    - 3.2.3.1 Bivalent Pk Trisaccharides, 136
    - 3.2.3.2 Decavalent Pk Ligands, 137
    - 3.2.3.3 Polyvalent Polymeric Pk Ligands, 139
    - 3.2.3.4 Multivalent Presentation of P<sub>1</sub> on a Solid Support, 140
  - 3.2.4 Verotoxin, 141
  - 3.2.5 *Bacillus anthracis* Anthrax Toxin, 141
    - 3.2.5.1 Polyvalent Peptide Inhibitors, 142
- 3.3 Bacterial Enzymes, 143
  - 3.3.1 Transpeptidases, 143
    - 3.3.1.1 Divalent Substrates, 143
    - 3.3.1.2 Multivalent  $\beta$ -Lactams, 143
  - 3.3.2 *E. coli* Pyrophosphokinase, 146
  - 3.3.3 Protein Tyrosine Phosphatase, 147
  - 3.3.4 DNA Gyrase, 147
  - 3.3.5 Dihydrofolate Reductase, 148
  - 3.3.6 Sialidase (Neuraminidase), 150
  - 3.3.7 NAD Synthetase, 151
- 3.4 Bacterial Nucleic Acids, 152
  - 3.4.1 Ribosomal RNA, 152

- 3.4.1.1 Divalent Aminoglycosides, 152
- 3.4.1.2 Divalent Aminoglycoside Bound to a Dimerized A-Site, 153
- 3.4.1.3 Polyvalent Polymeric Amikacin Derivatives, 154
- 3.5 Multivalent Molecules as Synthetic Vaccines, 155
  - 3.5.1 Synthetic *Shigella* Vaccines, 155
  - 3.5.2 Synthetic *Mycobacterium* Vaccines, 155
  - 3.5.3 Carbohydrate Vaccines against Leishmaniasis, 156
  - 3.5.4 Capsular Polysialic Acid Presented on Liposomes, 157
  - 3.5.5 Multivalent Carbohydrate Antigens from *Streptococcus*, 158
- 3.6 Fungal Cells, 160
  - 3.6.1 Covalent Dimer of Amphotericin B, 160

#### **4 Multivalent Molecules Applied to Cellular Targets 162**

- 4.1 Carbohydrate-Recognition Receptors on Cell Surfaces, 162
  - 4.1.1 Hepatic Mannose/*N*-Acetylgalactosamine-4-SO<sub>4</sub> Receptors, 162
    - 4.1.1.1 Glycoprotein-Based Multivalent Ligands, 162
  - 4.1.2 Hepatic Asialoglycoprotein Receptors, 164
    - 4.1.2.1 Triantennary Galactosides, 164
    - 4.1.2.2 Lysine-Based Multivalent *N*-Acetylgalactosides, 164
    - 4.1.2.3 Trivalent Galactoside–Cholesterol Conjugates, 165
    - 4.1.2.4 Trivalent Galactosides for Cell-Specific DNA Delivery, 168
    - 4.1.2.5 Multivalent Binding and Intracellular Trafficking, 169
  - 4.1.3 Mannose-Binding Proteins, 169
    - 4.1.3.1 Bivalent Mannosides, 171
    - 4.1.3.2 Mannose-Presenting Neoglycoproteins, 172
    - 4.1.3.3 GlcNAc-Presenting Polymer, 172
    - 4.1.3.4 Mannoside Mimics, 173
  - 4.1.4 Mannose 6-Phosphate Receptor (Insulinlike Growth Factor II), 174
    - 4.1.4.1 Neoglycoprotein-Based Mannose-6-Phosphate, 175
    - 4.1.4.2 Biotin/Avidin-Based Tetraivalent Mannose-6-Phosphate, 176
  - 4.1.5 Galectins, 177

- 4.1.5.1 Glycodendrimer, 177
- 4.1.6 Sialoadhesin CD22, 179
- 4.1.7 Dendritic Cell-Specific ICAM-3-Grabbing Nonintegrin, 180
  - 4.1.7.1 Mannoside Clusters on Peptide and Protein Scaffolds, 180
  - 4.1.7.2 Lewis Saccharide-Presenting Dendrimers, 181
- 4.1.8 Spermatogenesis, 181
- 4.1.9 Sperm-Egg Interactions, 182
  - 4.1.9.1 Bindin, 182
  - 4.1.9.2  $\beta$ -1,4-Galactosyltransferase, 183
  - 4.1.9.3 Fertilin  $\beta$ , 183
  - 4.1.9.4 XL35 Lectin, 183
- 4.1.10 Fucose-Binding Receptor on Cancer Cells, 184
  - 4.1.10.1 Fucose-Batracylin Conjugate Based on Neoglycoprotein, 184
  - 4.1.10.2 Liposomes That Display GM<sub>3</sub>-lac Ceramide, 185
- 4.1.11 Fibroblast Growth Factors, 186
- 4.1.12 Carbohydrate-Carbohydrate Interactions at Cell Surfaces, 186
  - 4.1.12.1 Gg<sub>3</sub>-GM<sub>3</sub> Interaction, 186
  - 4.1.12.2 Aggregation Factors of Marine Sponges, 187
  - 4.1.12.3 Le<sup>x</sup>-Le<sup>x</sup> Interaction, 188
- 4.1.13 E-Selectin, 188
  - 4.1.13.1 Divalent Sialyl Lewis x, 189
  - 4.1.13.2 Trivalent Sialyl Lewis x Constructs, 189
  - 4.1.13.3 Neoglycoproteins Displaying Sialyl Lewis x Ligands, 191
  - 4.1.13.4 Liposomes Displaying Sialyl Lewis x, 192
  - 4.1.13.5 Polyvalent Polymeric Sialyl Lewis x, 195
  - 4.1.13.6 Sialyl Le<sup>x</sup>-Binding Multivalent Receptors, 198
- 4.1.14 L-Selectin, 198
  - 4.1.14.1 Divalent Sulfated Lactoside, 200
  - 4.1.14.2 Neoglycopolymers Presenting Sialyl Le<sup>x</sup>, 201
  - 4.1.14.3 Poly(acrylamide) Scaffolds That Present Sulfated Le<sup>x</sup>, 203
  - 4.1.14.4 Poly(lactosamine) Scaffolds That Present SLe<sup>x</sup>, 203
- 4.1.15 P-Selectin, 204
  - 4.1.15.1 Sialyl Lewis x-RGD Conjugates, 205

- 4.1.15.2 Copolymers Presenting Sialyl Le<sup>a</sup> Residues and Sulfated Tyrosines, 205
- 4.1.15.3 Neoglycopolymers Presenting Sulfated Galactosides, 206
- 4.1.15.4 Polymerized Liposomes Presenting Mimetics of Sialyl Lewis x, 206
- 4.1.16 Lectins, 209
  - 4.1.16.1 Oligovalent Mannosides Binding to Con A, 209
  - 4.1.16.2 Trivalent Mannosides on a Rigid Scaffold, 209
  - 4.1.16.3 Bifunctional Multivalent Glycosides Binding to Con A, 211
  - 4.1.16.4 Heptavalent Mannosides Linked to  $\beta$ -Cyclodextrin, 211
  - 4.1.16.5 Mannosides Displayed on a Benzene- or Peptide-Based Dendrimer, 211
  - 4.1.16.6 Poly(oxanorbornene) Presenting Glucosides, 215
  - 4.1.16.7 Poly(norbornene) Derivatives Bearing Two Types of Ligands, 217
  - 4.1.16.8 Glycopolymer-Mediated Cell–Cell Adhesion, 217
  - 4.1.16.9 Mannosides Displayed on Self-Assembled Monolayers, 218
  - 4.1.16.10 Multivalent Galactosides Binding to *Bauhinia purpurea* Lectin, 218
  - 4.1.16.11 Dendritic Sialosides Binding to *Limax flavus* Lectin, 219
  - 4.1.16.12 Dendritic GlcNAc Binding to Wheat Germ Agglutinin, 220
  - 4.1.16.13 Cyclodextrin-Based Multivalent Glucosides Binding to *Pisum sativum* Lectin, 222
  - 4.1.16.14 Oligovalent Mannosides Binding to *Dioclea grandiflora* Lectin, 223
  - 4.1.16.15 Polymeric Polyvalent Lactosides Binding to *Psophocarpus tetragonolobus* Lectin, 225
  - 4.1.16.16 Resin-Displayed Multivalent Galactosides Binding to RCA Lectin, 225
  - 4.1.16.17 Liposome-Based Multivalent Galactosides Binding to RCA Lectin, 226
  - 4.1.16.18 Multivalent Display of Saccharides on Microtiter Well Surfaces, 227
- 4.2 Peptide and Hormone Recognition Receptors on Cell Surfaces, 228

- 4.2.1 CD14 Glycoprotein, 228
  - 4.2.1.1 Poly(acrylamide) Displaying Muramyl Dipeptides, 228
- 4.2.2 Major Histocompatibility Complex, 229
  - 4.2.2.1 MHC Peptides Tethered to a Peptide Scaffold, 229
- 4.2.3 Integrins, 231
  - 4.2.3.1 Poly(norbornene) Presenting RGD and PHSRN Sequences, 231
  - 4.2.3.2 GRGDS Displayed on Polystyrene Beads, 232
  - 4.2.3.3 RGD Peptides Presented on SAMs, 233
  - 4.2.3.4 Polymeric Nanoparticles Displaying  $\alpha_v\beta_3$  Antagonist, 233
  - 4.2.3.5 Divalent Antagonist of Integrin  $\alpha_v\beta_3$ , 234
- 4.2.4 Immunoglobulin, 235
  - 4.2.4.1 Pentavalent Peptides, 236
- 4.2.5 Estrogen Receptors, 236
- 4.3 Ligand-Mediated Receptor Dimerization, 236
  - 4.3.1 Chemical Inducers of Dimerization, 236
    - 4.3.1.1 Natural Heterodimerizers, 237
    - 4.3.1.2 FK506 Dimer (FK1012), 238
    - 4.3.1.3 FK506 Mimetics and CIDs, 239
    - 4.3.1.4 Cyclosporin Dimer, 240
    - 4.3.1.5 Heterodimeric CIDs Composed of FK506 and Cyclosporin, 241
    - 4.3.1.6 Heterodimeric CIDs Composed of FK506 and SH2 Ligands, 241
    - 4.3.1.7 Bivalent Ligands Binding to FKBP, 245
    - 4.3.1.8 Rapamycin-Mediated Association of Inteins, 245
  - 4.3.2 Cytokine Receptors, 246
    - 4.3.2.1 Divalent EPO Mimetics, 247
    - 4.3.2.2 Divalent Peptide Antagonists of IL-5, 247
    - 4.3.2.3 Dimeric Mimetics of G-CSF, 247
    - 4.3.2.4 Dimeric Mimetics of NT-3, 249
  - 4.3.3 Vitamin D<sub>3</sub> Receptors, 250
- 4.4 Enzymes, 250
  - 4.4.1 Acetylcholinesterase, 250
    - 4.4.1.1 Tetrahydroacridine Dimer, 250
    - 4.4.1.2 Huperzine Dimer, 252
    - 4.4.1.3 Surface Anchoring, 252
  - 4.4.2 Matrix Metalloproteinases, 252
  - 4.4.3 Trypsin, 253

- 4.4.3.1 Bivalent Inhibitors Tethered to Cyclodextrin, 254
- 4.4.3.2 Bivalent Inhibitors Tethered to Diketopiperazine, 255
- 4.4.3.3 Benzamidine-Based Divalent Inhibitors, 255
- 4.4.4 Proteasomes, 256
  - 4.4.4.1 Multivalent Nature of Proteasomes, 256
  - 4.4.4.2 PEG-Linked Tripeptide Dimers, 257
- 4.4.5 Protein Kinase C, 258
  - 4.4.5.1 Divalent Nature of Protein Kinase C, 258
  - 4.4.5.2 Phorbol Dimers, 258
- 4.4.6 Syk Protein Tyrosine Kinase, 259
- 4.4.7 Protein Tyrosine Phosphatases, 259
  - 4.4.7.1 Phosphophenol Dimers, 259
  - 4.4.7.2 Divalent Tetronic Acids, 261
- 4.4.8 Human Leukocyte Elastase, 261
- 4.4.9 Thrombin, 261
- 4.4.10 Glucoamylase, 262
  - 4.4.10.1 Acarbose Linked to  $\beta$ -Cyclodextrin, 262
- 4.4.11 Glycosyltransferase, 264
  - 4.4.11.1 Divalent Inhibitors of  $\alpha$ 1,3-Galactosyltransferase, 264
  - 4.4.11.2 Divalent Inhibitors of  $\beta$ 1,4-Galactosyltransferase, 264
  - 4.4.11.3 Divalent Inhibitors of  $\alpha$ 1,2-Fucosyltransferase, 266
  - 4.4.11.4 Divalent Inhibitors of Sialyltransferase, 266
- 4.4.12 Riboflavin Synthase, 267
  - 4.4.12.1 Lumazine Dimers, 267
- 4.4.13 Lactate Dehydrogenase, 267
  - 4.4.13.1 Enzyme Oligomerization, 267
  - 4.4.13.2 Cyclodextrin Dimers, 268
- 4.4.14 Zinc-Dependent Enzymes, 269
  - 4.4.14.1 Histone Deacetylase, 269
  - 4.4.14.2 Carbonic Anhydrase, 270
- 4.5 G-Protein-Coupled Receptors, 270
  - 4.5.1  $\beta$ -Adrenergic Receptors, 270
    - 4.5.1.1 Divalent Ligands of  $\beta$ -AR, 271
    - 4.5.1.2 Isoproterenol Presented on Polypeptides, 272
    - 4.5.1.3 Practolol Dimers, 272
    - 4.5.1.4 Propranolol Dimers, 272
    - 4.5.1.5 Alprenolol Displayed on Dextran, 273
  - 4.5.2  $\alpha$ -Adrenergic Receptors, 274

- 4.5.2.1 Prazocin Dimers, 274
- 4.5.2.2 Yohimbine Dimers, 275
- 4.5.3 Opioid Receptors, 275
  - 4.5.3.1 Oxymorphanine Dimers, 276
  - 4.5.3.2 Bivalent Bridging, 276
- 4.5.4 Serotonin Receptors, 277
  - 4.5.4.1 Carboxamidoindole Dimers, 278
  - 4.5.4.2 Sumatriptan Dimer, 278
  - 4.5.4.3 Divalent SERT Inhibitors, 278
  - 4.5.4.4 Serotonin Displayed on Nanocrystals, 280
- 4.5.5 Muscarinic Acetylcholine Receptors, 280
  - 4.5.5.1 Quinuclidine Dimers, 280
- 4.5.6 Melanocortin-1 Receptor, 281
  - 4.5.6.1 Divalent  $\alpha$ -MSH Peptides, 281
- 4.6 Ion Channels, 282
  - 4.6.1 Cyclic Nucleotide-Gated Channels, 282
    - 4.6.1.1 Cyclic Nucleotides, 282
    - 4.6.1.2 PEG-Linked cGMP Dimers, 282
  - 4.6.2 IP<sub>3</sub>-Gated Calcium Channels, 283
    - 4.6.2.1 PEG-Linked IP<sub>3</sub> Dimers, 283
  - 4.6.3 Potassium Channels, 284
    - 4.6.3.1 Bisquinolinium, 284
  - 4.6.4 Nicotinic Acetylcholine Receptor, 285
    - 4.6.4.1 Succinylcholine, 285
- 4.7 Nucleic Acids, 286
  - 4.7.1 DNA Intercalators, 286
    - 4.7.1.1 Anthraquinone Linked to an Aminosugar, 286
    - 4.7.1.2 Daunorubicin Dimer, 287
    - 4.7.1.3 Bisacridine, 288
    - 4.7.1.4 Naphthalimide Dimers, 290
  - 4.7.2 Minor Groove Binders, 291
    - 4.7.2.1 Calicheamicin-Based Dimers, 291
    - 4.7.2.2 Mitomycin Dimers, 292
    - 4.7.2.3 Cyclopropa[*c*]pyrrolo [3,2-*e*]indole Dimers, 293
    - 4.7.2.4 Pyrrolo[2,1-*c*][1,4]benzodiazepine Dimers, 294
    - 4.7.2.5 PBD-Containing Heterodimers, 295
    - 4.7.2.6 DNA-Binding Polyamides, 295
    - 4.7.2.7 H-Shaped Polyamide Dimers, 296
    - 4.7.2.8 Hairpin-Shaped Polyamide Dimers, 297
    - 4.7.2.9 Hairpin-Shaped Extended Polyamides, 299
    - 4.7.2.10 Ring-Shaped Polyamide Dimers, 299
    - 4.7.2.11 Tetravalent Polyamides, 299

- 4.7.2.12 Polyamide–DNA Alkylator Conjugates, 299
- 4.7.2.13 Polyamides Linked to Camptothecin, 300
- 4.7.2.14 Polyamides Linked to Transcription Activators, 301
- 4.7.3 Divalent Recognition at Abasic Sites, 303
  - 4.7.3.1 Adenine Tethered to Acridine, 304
- 4.7.4 Divalent Binding to Guanine–Guanine Pairs, 304
  - 4.7.4.1 Naphthyridine Dimers, 304
- 4.7.5 Basic Leucine Zipper Proteins, 304
  - 4.7.5.1 bZIP-Derived Peptide Dimers, 304
  - 4.7.5.2 Divalent bZIP Moieties Linked to Chiral Templates, 305
  - 4.7.5.3 Divalent bZIP Moieties Tethered to an Azobenzene Scaffold, 305
- 4.8 Antibodies, 306
  - 4.8.1 Anticancer Vaccines, 306
    - 4.8.1.1 Tumor Cell Marker, 306
    - 4.8.1.2 Globo-H Presented on Keyhole Limpet Hemocyanin, 307
    - 4.8.1.3 GM<sub>3</sub> Presented on Bovine Serum Albumin, 309
    - 4.8.1.4 GM<sub>2</sub> Presented on KLH, 310
    - 4.8.1.5 T<sub>N</sub> Clusters Presented on KLH, 310
    - 4.8.1.6 T<sub>F</sub>-Presenting Dendrimers, 312
    - 4.8.1.7 Neoglycoproteins Presenting Multiple Tumor-Associated Antigens, 312
  - 4.8.2 Surface Epitopes Not Related to Cancer, 313
  - 4.8.3 Miscellaneous Epitopes, 314
- 4.9 Cell Surface Engineering, 315
  - 4.9.1 Metabolic Incorporation of Unnatural Carbohydrate Antigens, 315
    - 4.9.1.1 *N*-Butanoylsialic Acid, 316
    - 4.9.1.2 *N*-Levulinoyl Neuraminic Acid, 316
    - 4.9.1.3 Azidoacetyl Neuraminic Acid, 319
  - 4.9.2 (Bio)chemical Modification of Cell Surface Antigens, 320

## 5 Chemical Synthesis of Multivalent Molecules

321

- 5.1 Selected Synthetic Methods for Multimerization, 321
  - 5.1.1 Summary of Linker Chemistry, 321
  - 5.1.2 Polymerization, 323
  - 5.1.3 Self-Assembly, 325
  - 5.1.4 Solid-Phase Synthesis, 325

- 5.2 Combinatorial Chemistry, 325
  - 5.2.1 Structure-Biased Combinatorial Synthesis, 325
    - 5.2.1.1 Heterodimeric Inhibitors of Picorna Virus, 325
    - 5.2.1.2 Polyvalent Inhibitors of Influenza Virus, 327
    - 5.2.1.3 Heterodimeric Inhibitors of NAD Synthetase, 328
    - 5.2.1.4 Disulfide-Linked Heterodimers, 328
  - 5.2.2 Target-Guided Combinatorial Synthesis, 330
    - 5.2.2.1 FK-506 Binding Protein, 330
    - 5.2.2.2 Caspase, 331
    - 5.2.2.3 c-Src Kinase, 332
    - 5.2.2.4 Acetylcholine Esterase, 333
    - 5.2.2.5 Carbonic Anhydrase, 334
    - 5.2.2.6 Kallikrein, 334
  - 5.2.3 Dynamic Combinatorial Synthesis, 334
    - 5.2.3.1 Disulfide Exchange, 336
    - 5.2.3.2 Olefin Metathesis, 336
    - 5.2.3.3 Transition Metal Complexes, 337

**Appendix****339**

- Table 1. Divalent Ligands Linked to Enzymes in Human Immunodeficiency Virus (HIV), 339
- Table 2. Multivalent Ligands Linked to gp120 Surface Receptors in Human Immunodeficiency Virus, 340
- Table 3. Multivalent Ligands Linked to Surface Receptors on Viruses, 341
- Table 4. Multivalent Receptors Targeting Multivalent Ligands in Bacterial Cell Walls, 343
- Table 5. Multivalent Ligands Targeting Bacterial Receptors in Membrane Surfaces, 344
- Table 6. Multivalent Ligands Linked to Bacterial Toxins, 345
- Table 7. Multivalent Molecules Targeting Bacterial Enzymes, 346
- Table 8. Multivalent Ligands Targeting Carbohydrate-Recognition Receptors on Cellular Surfaces, 347
- Table 9. Multivalent Ligands Targeting Noncarbohydrate-Recognition Receptors on Cellular Surfaces, 350
- Table 10. Multivalent Ligands Linked to Selectins on Cell Surfaces, 352
- Table 11. Multivalent Ligands Linked to Lectins, 354
- Table 12. Multivalent Ligands Linked to Cellular Enzymes, 357
- Table 13. Multivalent Ligands Linked to G-Protein-Coupled Receptors (GPCRs), 359
- Table 14. Multivalent Ion Channel-Binding Molecules, 360

Table 15. Homo- and Heterodivalent Chemical Inducers of Dimerization (CIDs), 361	
Table 16. Multivalent Ligands Linked to Nucleic Acids, 362	
Table 17. Synthetic Multivalent Antigens, 365	
Table 18. Multivalent Ligands Displayed on Self-Assembled Monolayer (SAM) Made of Alkanethiolate on Gold, 367	
Table 19. (Bio)chemical Modification of Cell Surface Antigens, 368	
Table 20. Multivalent Targets, 369	

<b>References</b>	<b>371</b>
-------------------	------------

<b>Index</b>	<b>409</b>
--------------	------------

